NCT01837251已完成3 期
A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 682
- 试验地点
- 192
- 主要终点
- investigator-determined progression-free survival
研究概览
简要总结
Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of epithelial ovarian carcinoma or fallopian tube carcinoma or primary peritoneal carcinoma
- •First disease recurrence >6 months after first-line platinum-based chemotherapy
- •Patients with measurable or non-measurable disease (RECIST v1.1) or CA 125 assessable disease (GCIG criteria) or histological proven diagnosis of relapse
- •In case of cytoreductive surgery for recurrence, patients must be able to commence cytotoxic chemo-therapy within 8 weeks after cytoreductive surgery
- •ECOG PS 0-2
- •Absolute Neutrophil Count >= 1.5 x 10^9/L; Platelets >= 100 x 10^9/L; Hemoglobin >= 9.5 g/dL
- •Patients not receiving anticoagulant medication who have an International Normalized Ratio <= 1.5 and an Activated ProThrombin Time <= 1.5 x ULN
- •Serum bilirubin <= 2 x ULN; Serum transaminases <= 2.5 x ULN (<= 5 x ULN in the presence of liver metastasis)
- •Serum creatinine < 1.6 mg/dL or creatinine clearance >= 40 mL/min; Glomerular filtration rate > 40 ml/min (estimates based on the Cockroft-Gault or Jelliffe formula); Urine dipstick for proteinuria < 2+. If urine dipstick is >= 2+, 24 hour urine collection must demonstrate <= 1 g of protein in 24 hours
- •Normal blood pressure or adequately treated and controlled hypertension (either systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg)
排除标准
- •Ovarian tumors of low malignant potential
- •Malignancies other than ovarian cancer within 5 years prior to randomization
- •Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period
- •Any previous radiotherapy to the abdomen or pelvis
- •Known hypersensitivity to used chemotherapeutic agents in this trial and bevacizumab and its excipients, chinese hamster ovary cell products or other recombinant human or humanised antibodies
- •Current or recent chronic use of aspirin > 325 mg/day
- •Surgery (including open biopsy) within 4 weeks prior to anticipated first dose of Bevacizumab
- •History of VEGF therapy related abdominal fistula or gastrointestinal perforation
- •Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease
- •Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure
- •Previous Cerebro-Vascular Accident , Transient Ischaemic Attack or Sub-Arachnoid Haemorrhage
- •Prior history of hypertensive crisis or hypertensive encephalopathy
- •Clinically significant disease, including: myocardial infarction or unstable angina within ≤ 6 months of randomization; New York Heart Association (NYHA) >= grade 2 Congestive Heart Failure; poorly controlled cardiac arrhythmia despite medication; peripheral vascular disease grade >= 3
- •LVEF defined by ECHO/MUGA below the institutional lower limit of normal
- •Significant traumatic injury during 4 weeks prior to randomization
- •Current brain metastases or spinal cord compression
- •History or evidence upon neurological examination of central nervous system disease
- •Non-healing wound, active ulcer or bone fracture
- •History or evidence of thrombotic or hemorrhagic disorders within 6 months prior to randomization
- •Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic coagulation)
- •Fertile woman of childbearing potential not willing to use adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) for the duration of the trial and at least 6 months afterwards
- •Pregnant or lactating women
- •Requirement of therapeutic anticoagulation using marcumar, warfarin or PTT-prolonging heparin
研究组 & 干预措施
Research Arm
Experimental
Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
干预措施: Carboplatin (Drug)
Research Arm
Experimental
Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
干预措施: PLD (Drug)
Research Arm
Experimental
Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
干预措施: Bevacizumab (Biological)
结局指标
主要结局
investigator-determined progression-free survival
时间窗: every 12 weeks until progression or up to 30 months (whichever occurs first)
次要结局
- Health related Quality of Life (QoL)(Baseline and then every 12 weeks until investigator-determined progresssion-free survival and thereafter at every visit for th 5-years follow-up or death (whichever occurs first))
- Safety and Tolerability, i.e. type, frequency, severity and duration o adverse reactions(every 3 weeks, 30 months after start of treatment or if applicable 4 weeks after last dose of bevacizumab (whichever occurs later))
- Overall Survival(every 3 weeks during treatment with bevacizumab, thereafter every 6 months; for up 30 months)
- biological progression-free survival by serum CA 125(every 3 weeks until progression or up to 30 months (whichever occurs first))
研究者
研究点 (192)
Loading locations...
相似试验
已完成
3 期
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian CancerOvarian CancerNCT04908787Jiangsu Simcere Pharmaceutical Co., Ltd.421
Unknown
3 期
Hydralazine Valproate for Ovarian CancerOvarian CancerNCT00533299National Institute of Cancerología211
已完成
2 期
Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase InhibitorPlatinum Refractory Epithelial Ovarian CancerPrimary Cancer of the PeritoneumCancer of the Fallopian TubeNCT00543049AGO Study Group73
招募中
不适用
Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian CancerRecurrent Epithelial Ovarian CancerNCT05444270Yonsei University270
进行中（未招募）
不适用
Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapyPlatinum refractory or resistant ovarian cancer, primary cancer of the peritoneum or fallopian tube (defined as stable (SD) or progressive disease (PD) during platinum containing chemotherapy, or treatment free interval < 6 months after stop of platinum based chemotherapy)EUCTR2007-003089-16-DEAGO Research GmbH72